Clinical studies have shown GLP-1 receptor agonists may reduce high-sensitivity C-reactive protein (hs-CRP), tumour necrosis factor-alpha (TNF-), interleukin-6 (IL-6), and interleukin-1 beta (IL-1)
However, loss of IL-1R signaling does not impact LPS-mediated GLP-1 secretion, as shown in Il1r / mice while neither LPS nor IL-1 stimulate GLP-1 secretion in Il6 / mice (Kahles et al., 2014)
The effects of GLP-1 and dual agonists on lipid metabolism also provide a more complete treatment plan for metabolic diseases
Plus, says Vash, when you go to the bathroom, the medication causes an oily discharge. (Thats the fat your body isnt absorbing.) And, he says, orlistat results in an average 6% weight loss, which is much lower than other weight-loss medications
The Wall Street Journal describes it the King Kong of weight loss drugs